A Patient and Investigator-blinded, Randomized, Placebo Controlled Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2018
At a glance
- Drugs LLG 783 (Primary)
- Indications Intermittent claudication; Peripheral arterial disorders
- Focus Adverse reactions; Therapeutic Use
- Acronyms PAD PoC
- Sponsors Novartis Pharmaceuticals
- 28 May 2018 Planned number of patients changed from 40 to 44.
- 28 May 2018 Planned End Date changed from 29 Dec 2018 to 28 Dec 2018.
- 28 May 2018 Planned primary completion date changed from 29 Dec 2018 to 15 Aug 2018.